David H Ipsen
Overview
Explore the profile of David H Ipsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skat-Rordam J, Pedersen K, Skovsted G, Gregersen I, Vangsgaard S, Ipsen D, et al.
Antioxidants (Basel)
. 2022 Jan;
11(1).
PMID: 35052573
Oxidative stress is directly linked to non-alcoholic fatty liver disease (NAFLD) and the progression to steaotohepatitis (NASH). Thus, a beneficial role of antioxidants in delaying disease progression and/or accelerating recovery...
2.
Skat-Rordam J, Ipsen D, Seemann S, Latta M, Lykkesfeldt J, Tveden-Nyborg P
Biomedicines
. 2021 Sep;
9(9).
PMID: 34572384
The successful development of effective treatments against nonalcoholic steatohepatitis (NASH) is significantly set back by the limited availability of predictive preclinical models, thereby delaying and reducing patient recovery. Uniquely, the...
3.
Zisser A, Ipsen D, Tveden-Nyborg P
Biomedicines
. 2021 Apr;
9(4).
PMID: 33807461
Hepatic fibrosis is the primary predictor of mortality in patients with non-alcoholic steatohepatitis (NASH). In this process, the activated hepatic stellate cells (HSCs) constitute the principal cells responsible for the...
4.
Ipsen D, Lykkesfeldt J, Tveden-Nyborg P
Adv Nutr
. 2020 Nov;
11(6):1696-1711.
PMID: 33191435
Nonalcoholic steatohepatitis (NASH) is one of the most common chronic liver diseases in the world, yet no pharmacotherapies are available. The lack of translational animal models is a major barrier...
5.
Klaebel J, Skjodt M, Skat-Rordam J, Rakipovski G, Ipsen D, Schou-Pedersen A, et al.
Nutrients
. 2019 Nov;
11(11).
PMID: 31752351
Despite affecting millions of patients worldwide, no pharmacological treatment has yet proved effective against non-alcoholic steatohepatitis (NASH) induced liver fibrosis. Current guidelines recommend lifestyle modifications including reductions in dietary energy...
6.
Jensen V, Tveden-Nyborg P, Zacho-Rasmussen C, Quaade M, Ipsen D, Hvid H, et al.
J Pharmacol Toxicol Methods
. 2019 Nov;
101:106651.
PMID: 31733366
Introduction: In animal models of non-alcoholic fatty liver disease (NAFLD), assessment of disease severity and treatment effects of drugs rely on histopathological scoring of liver biopsies. However, little is known...
7.
Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis
Ipsen D, Rolin B, Rakipovski G, Skovsted G, Madsen A, Kolstrup S, et al.
Basic Clin Pharmacol Toxicol
. 2018 Jun;
123(6):704-713.
PMID: 29953740
Although commonly associated with obesity, non-alcoholic fatty liver disease (NAFLD) is also present in the lean population representing a unique disease phenotype. Affecting 25% of the world's population, NAFLD is...
8.
Ipsen D, Tveden-Nyborg P, Lykkesfeldt J
Curr Obes Rep
. 2016 Oct;
5(4):405-412.
PMID: 27687811
Purpose Of Review: Purpose of review: It is becoming increasingly clear that some obese individuals do not develop dyslipidemia and instead remain healthy, while some normal weight individuals become dyslipidemic...
9.
Tveden-Nyborg P, Birck M, Ipsen D, Thiessen T, Feldmann L, Lindblad M, et al.
Transl Res
. 2015 Nov;
168:146-160.
PMID: 26518991
Chronic dyslipidemia imposed by a high-fat and high-caloric dietary regime leads to debilitating disorders such as obesity, nonalcoholic fatty liver disease (NAFLD), and insulin resistance. As disease rates surge, so...